tirzepatide .5 5mg GIP/GLP-1 Receptor Agonist Lilly releases Zepbound® (tirzepatide) single-dose

Begin at roughly half the target dose, or less, for the first 5 to 7 days

Zambrano, M

When you're investing significant time and capital into a study, the quality of your base materials is not the place to cut corners

GLP-1 medications help people with obesity lose weight, and losing weight often leads to fewer PCOS symptoms

This has been developed as a formulation with a transepithelial enhancer, but paltusotine is a non-octreotide molecule effective as once-daily administration, taken first thing in the morning before breakfast, similar to thyroxine dosing. This latter paper is Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine and published in December 2024, by Mnica R

Until proper human trials are conducted, users are essentially volunteering as test subjects in an uncontrolled experiment with their own bodies.